Surveillance of genetic markers associated with *Plasmodium falciparum* resistance to artemisinin-based combination therapy in Pakistan, 2018–2019

Abdul Qader Khan1,2, Leyre Pernaute-Lau2,3, Aamer Ali Khattak4, Sanna Luijcx2, Berit Aydin-Schmidt2, Mubashir Hussain1, Taj Ali Khan1, Farees Uddin Mufti5 and Ulrika Morris2*

**Abstract**

**Background:** The spread of artemisinin resistance in the Greater Mekong Subregion of Southeast Asia poses a significant threat for current anti-malarial treatment guidelines globally. The aim of this study was to assess the current prevalence of molecular markers of drug resistance in *Plasmodium falciparum* in the four provinces with the highest malaria burden in Pakistan, after introducing artemether–lumefantrine as first-line treatment in 2017.

**Methods:** Samples were collected during routine malaria surveillance in Punjab, Sindh, Baluchistan, and Khyber Pakhtunkhwa provinces of Pakistan between January 2018 and February 2019. *Plasmodium falciparum* infections were confirmed by rapid diagnostic test or microscopy. *Plasmodium falciparum* positive isolates (*n* = 179) were screened by Sanger sequencing for single nucleotide polymorphisms (SNPs) in the *P. falciparum kelch 13* (*pfk13*) propeller domain and in *P. falciparum coronin* (*pfcoronin*). SNPs in *P. falciparum multidrug resistance 1* (*pfmdr1*) N86Y, Y184F, D1246Y and *P. falciparum chloroquine resistance transporter* (*pfcrt*) K76T were genotyped by PCR-restriction fragment length polymorphism.

**Results:** No artemisinin resistance associated SNPs were identified in the *pfk13* propeller domain or in *pfcoronin*. The *pfmdr1* N86, 184F, D1246 and *pfcrt* K76 alleles associated with reduced lumefantrine sensitivity were present in 83.8% (150/179), 16.9% (29/172), 100.0% (173/173), and 8.4% (15/179) of all infections, respectively. The chloroquine resistance associated *pfcrt* 76T allele was present in 98.3% (176/179) of infections.

**Conclusion:** This study provides an update on the current prevalence of molecular markers associated with reduced *P. falciparum* sensitivity to artemether and/or lumefantrine in Pakistan, including a first baseline assessment of polymorphisms in *pfcoronin*. No mutations associated with artemisinin resistance were observed in *pfk13* or *pfcoronin*. However, the prevalence of the *pfmdr1* N86 and D1246 alleles, that have been associated with decreased susceptibility to lumefantrine, remain high. Although clinical and molecular data suggest that the current malaria treatment guidelines for *P. falciparum* are presently effective in Pakistan, close monitoring for artemisinin and lumefantrine resistance will be critical to ensure early detection and enhanced containment of emerging ACT resistance spreading across from Southeast Asia.

*Correspondence: ulrika.morris@ki.se*

2 Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden

Full list of author information is available at the end of the article
Keywords: *Plasmodium falciparum*, Pakistan, Artemisinin-based combination therapy, Artemether–lumefantrine, Chloroquine, Drug resistance, *P. falciparum coronin*, *P. falciparum kelch* 13 propeller domain, *pfcr*, *pfmdr1*

Background

Despite ongoing global efforts to control and eradicate malaria, the disease remains a significant contributor to morbidity and mortality worldwide. According to the World Health Organization (WHO), there were over 228 million cases of malaria in 2018, resulting in approximately 405,000 deaths [1]. In Pakistan, malaria transmission is moderate, with approximately 60% of the population (123 million people) at high risk of contracting malaria. According to the Pakistan malaria annual report there were more than 300,000 confirmed malaria cases reported in 2018 [2]. Among these cases, 84% were caused by *Plasmodium vivax*, 15% by *Plasmodium falciparum*, and 1% were mixed *P. falciparum* and *P. vivax* infections.

Malaria control relies on a handful of interventions including prompt and effective treatment with artemisinin-based combination therapy (ACT); a strategy currently threatened by *P. falciparum* resistance to artemisinin and its partner drugs spreading across Southeast Asia [3, 4]. Artemisinin resistance was first reported in Cambodia in 2009 [5, 6], and is now widespread across the Greater Mekong Subregion [4, 7, 8]. It is phenotypically characterized by delayed parasite clearance following treatment, which has been associated with a number of single nucleotide polymorphisms (SNPs), including F446I, Y493H, R539T, I543T, and C580Y, in the propeller domain of the *P. falciparum kelch* 13 (*pfkl*3) gene [4, 9, 10]. Possible independent emergence of the *pfkl*3 C580Y mutation has been reported in Guyana [11] and Papua New Guinea [12], and candidate *pfkl*3 resistance mutations (P574L and A675V), which are common in southeast Asia and have been associated with delayed parasite clearance, have been identified in Rwanda [13]. Concomitant emergence of tolerance and/or resistance to the long-acting partner drugs in artemisinin-based combinations (namely, piperaquine, mefloquine, sulfadoxine-pyrimethamine, lumefantrine, and amodiaquine), has resulted in ACT failures in several areas of southeast Asia [3, 14–16]. Recently, delayed parasite clearance associated with polymorphisms in *pfkl*3 has been reported in Eastern India after treatment with artesunate-sulfadoxine-pyrimethamine (AS + SP) [17, 18].

The availability of molecular markers for both artemisinin- and partner drug resistance has greatly aided close surveillance of the emergence and spread of ACT resistance. In addition to *pfkl*3, SNPs in the *P. falciparum* actin-binding protein coronin (*pfcor*) gene (G50E, R100K, and E107V) have recently been identified to confer reduced in vitro sensitivity to artemisinin [19]. Whilst these mutations have yet to be found in vivo in samples from Africa or elsewhere [20], it has been suggested that *pfcor* mutants could emerge as a non-*pfkl*3 type of artemisinin resistance in natural settings [19]. Moreover, polymorphisms in the *P. falciparum* multidrug resistance 1 (*pfmdr1*) and *P. falciparum* chloroquine resistance transporter (*pfcr*) genes have been associated with decreased susceptibility to chloroquine, and important ACT partner drugs including lumefantrine, mefloquine, and amodiaquine [21–27].

After establishment of chloroquine resistance in Pakistan, the WHO recommended AS + SP for treatment of uncomplicated *P. falciparum* infections in 2007. However, after rapid increases in AS + SP treatment failure rates in Somalia and Sudan (ranging from 12% to 22%) [1, 4], and the recent reports from India [17, 18], the national treatment guidelines were updated in 2017 with artemether–lumefantrine (AL) given together with a single low dose of primaquine as recommended first-line treatment for uncomplicated *P. falciparum* malaria [1].

This study aims to provide an update on the current prevalence of molecular markers associated with drug resistance after introduction of AL as first-line treatment, in the four provinces with the highest malaria burden in Pakistan. This includes a first baseline assessment of polymorphisms in the *pfcor* gene and prevalence of SNPs in the *pfkl*3 propeller region, that have been associated with reduced sensitivity to artemisinin, as well as the proportions of infections harbouring the *pfmdr1* N86, 184F, D1246 and *pfcr* K76 alleles that have been associated with reduced sensitivity to lumefantrine [25, 28–36].

Methods

Study sites

Seventeen government and private hospitals in the four provinces with the highest malaria burden in Pakistan (Khyber Pakhtunkhwa (KPK), Sindh, Balochistan, and Punjab) were invited to provide blood samples during routine malaria surveillance. Ten facilities responded and were included in this study: Bannu, Kohat, Karak, Dera Ismail Khan, Frontier Region (FR) Khyber, FR Dera Ismael (DI) Khan, and Hangu in KPK province; Karachi in Sindh Province; Quetta in Balochistan Province; and Dera Ghazi Khan in Punjab Province (Fig. 1). Symptomatic, febrile patients who visited government and/or private hospitals in these selected sites between January
2018 and February 2019 were registered in this study. Written informed consent was obtained from all participants/guardians before collecting clinical history and venous blood samples.

**Samples storage and DNA extraction**

Approximately 5 ml of whole blood was collected in EDTA tubes from 209 patients with malaria infections confirmed by rapid diagnostic test and/or microscopy. Samples were shipped to Karolinska Institutet, Stockholm, Sweden for subsequent molecular analysis. DNA was extracted from 200 μl of whole blood using the QIAamp DNA mini kit (QIAGEN, Inc., Germany), following the manufacturer’s guidelines. Extracted DNA was stored at −20 °C.

**Sequencing of the pfk13 propeller domain and pfcoronin**

The 849 base pair fragment covering amino acid positions 407–689 in the pfk13-propeller domain was amplified with Q5 high-fidelity polymerase (New England Biolabs, UK) using a previously described nested polymerase chain reaction (PCR) protocol [9]. A *P. falciparum* 3D7 positive control and a no template control was included in each PCR. Amplified PCR products were separated by electrophoresis in 1.5% agarose gels stained with GelRed® (Biotium, USA). The 849-base pair fragment was extracted from the gel and purified using GeneJET Gel Extraction Kit (Thermo Fisher Scientific, Lithuania). The purified PCR products from clinical isolates and 3D7 positive control were sent for bidirectional Sanger sequencing at Macrogen, Netherlands. The sequencing data was analysed using Sequencher version 5.1 software (Gene Codes Corporation, USA). Generated sequences were aligned with the reference sequence of 3D7 (PlasmoDB gene ID: PF3D7_1343700). Nested PCR and sequencing were repeated in case of poor-quality sequencing output.

A 368 base pair fragment covering the region in the N-terminal WD40 domain of pfcoronin where all three SNPs associated with artemisinin resistance were reported [19], was amplified in a nested PCR. The following primers were used for the primary PCR: Pfcoronin-1st_fwd 5′-TGATTGTTCATATTATA GGTAC-3′ and Pfcoronin-1st_rev 5′-TATTCTGAC AAGTCCCCTTTATA-3′, and for the nested PCR: Pfcoronin-nest_fwd 5′-CATATTAGGTACCATG GCAAGTT-3′ and Pfcoronin-nest_rev 5′-AGGCTT TCTTCTCATTTCTATAC-3′. For the primary PCR, 1 μl of DNA was amplified with 1 μM of each primer, 0.2 mM dNTP, 3.75 mM MgCl₂, 1 × GoTaq reaction buffer, and 0.75U GoTaq DNA polymerase (Promega, USA), using the following cycling program:
30 s at 90 °C; followed by 30 cycles of 20 s at 90 °C, 30 s at 45 °C, 1.30 min at 68 °C. For the nested PCR, 1 µL of primary PCR products were amplified under the same conditions using the following cycling program: 30 s at 90 °C; followed by 45 cycles of 15 s at 94 °C, 30 s at 50 °C, 1 min at 68 °C. A 3D7 positive control and a no template control was included in each PCR. The nested PCR products were sent for direct bidirectional Sanger sequencing at Macrogen and analysed as described above with 3D7 as a reference (PlasmoDB gene ID: PF3D7_1251200).

**Genotyping of SNPs in pfmdr1 and pfcrt**
SNPs at positions pfmdr1 N86Y, Y184F, and D1246Y and pfcrt K76T were genotyped following nested PCR-restriction fragment length polymorphism (RFLP) protocols as summarized in [37]. Laboratory clones 3D7, Dd2, and 7G8 were included as positive and negative restriction controls, and a no template control was included in each PCR. 5 µL of each PCR amplicon was digested overnight with either Apol, MluCI or EcoV (New England Biolabs, UK), following manufacturer’s instructions. RFLP products were run on 2–2.5% agarose gels stained with GelRed® (Biotium, USA) and documented with a GelDoc™ system.

**Data analysis**
The prevalence of each SNP was defined as the proportion of isolates containing the allele of interest, including mixed infections. Isolates containing mixed SNP results at more than one position were excluded from the pfmdr1 haplotype analysis; frequencies for haplotypes were otherwise calculated as for the SNPs.

**Results**

**Study population**
In total, 209 uncomplicated *P. falciparum* cases from 10 different sites across the country were enrolled in this study between January 2018 and February 2019 (Table 1). Among rapid diagnostic rest and/or microscopy positive malarial isolates, 179 samples were confirmed as *P. falciparum* infections by PCR. Among the 179 PCR confirmed patients, 120 (67%) were male and 59 (33%) were female, with ages ranging from two to 65 years, and a median age of 25 years.

**Prevalence of SNPs in pfk13 and pfcoronin**
PCR success rates for the nested PCR amplifying the pfk13 propeller domain and pfcoronin were 97.7% (175/179) and 100% (179/179), respectively, of which 121 (69.1%) and 149 (83.2%) generated good quality sequences. No artemisinin resistance associated SNPs were identified in either of the analysed fragments, hence all successfully sequenced samples showed wild-type genotypes in both pfk13 and pfcoronin.

**Prevalence of SNPs in pfcrt and pfmdr1**
PCR success rates for the nested PCRs for determining SNPs in pfmdr1 N86Y and pfcrt K76T were 100% (179/179); PCR success rates for pfmdr1 Y184F and D1246Y were 96.1% (172/179) and 96.6% (173/179), respectively (Table 2). The pfmdr1 N86, 184F, D1246 and pfcrt K76 alleles that have been associated with reduced sensitivity to lumefantrine were present in 83.8% (150/179), 16.9% (29/172), 100.0% (173/173), and 8.4% (15/179) of all infections, respectively, with similar distribution across the four provinces (Fig. 2). The most common pfmdr1 haplotype was NYD present in 72.9% (121/166) of the samples, followed by

**Table 1** *Plasmodium falciparum* samples collected from 10 sites in Pakistan, 2018–2019

| Province            | City          | PCR-confirmed *P. falciparum* infection (N) | Sex (%male %female) | Median age (years [IQR])** |
|---------------------|---------------|--------------------------------------------|---------------------|---------------------------|
| Khyber Pakhtunkhwa  | Karak         | 10                                         | 60/40               | 35 [10–45]                |
|                     | Kohat         | 8                                          | 50/50               | 22 [14–28]               |
|                     | Dera Ismeel Khan | 10                                      | 90/10               | 25 [16–30]               |
|                     | Bannu         | 13                                         | 85/15               | 25 [7–36]                |
|                     | Hangu         | 5                                          | 40/60               | 25 [20–35]               |
|                     | FR Khyber     | 10                                         | 80/20               | 8 [4–20]                 |
|                     | FR DI Khan    | 12                                         | 83/17               | 13 [9–29]                |
| Punjab              | Dera Ghazi Khan | 53                                        | 60/40               | 30 [15–40]               |
| Sindh               | Karachi       | 41                                         | 60/40               | 25 [15–37]               |
| Baluchistan         | Quetta        | 17                                         | 76/24               | 28 [21–40]               |
| Total               |               | 179                                        | 68/32               | 25 [2–60]                |

* IQR, interquartile range
pfmdr1 YYD in 22.9% (38/166), and pfmdr1 NFD in 15.1% (25/166) of the samples. The pfcrt 76T allele that is associated with chloroquine resistance was found in 98.3% (176/179) of the samples.

Table 2 Prevalence of SNPs in pfk13, pfcoronin, pfcrt, and pfmdr1 in Pakistan, 2018–2019

| Gene        | N   | Wild Typea N (%) | Mutantb N (%) | Mixedc N (%) |
|-------------|-----|-----------------|---------------|--------------|
| PfK13       | 121 | 121 (100)       | 0 (0)         | 0 (0)        |
| Pfcoronin   | 149 | 149 (100)       | 0 (0)         | 0 (0)        |
| Pfmdr1 N86Y | 179 | 137 (76.5)      | 29 (16.2)     | 13 (7.3)     |
| Pfmdr1 Y184F| 172 | 143 (83.1)      | 18 (10.5)     | 11 (6.4)     |
| Pfmdr1 D1246Y| 173 | 173 (100)       | 0 (0)         | 0 (0)        |
| Pfcrt K76T  | 179 | 3 (1.7)         | 164 (91.2)    | 12 (6.7)     |

a Wild type alleles include Pfmdr1 N86, Y184, D1246, and Pfcrt K76
b Mutant alleles include Pfmdr1 86Y, 184F, 1246Y, and Pfcrt 76T
c Mixed alleles include Pfmdr1 N86Y, Y184F, D1246Y and Pfcrt K76T mixed infections

Discussion

Pakistan has set a target to reduce the malaria burden by 75% in high endemic districts and to eliminate malaria in low endemic districts by 2020 [2]. However, if artesiminin resistance continues to spread westward from neighbouring regions in South East Asia, then efforts in further controlling and eliminating malaria will be largely hampered [38]. Early surveillance of antimalarial drug resistance through molecular epidemiological studies, is in such, essential for achieving these targets. This study provides an update on the current prevalence of molecular markers associated with drug resistance in Pakistan after the introduction of AL as first-line treatment in 2017, including a first baseline assessment of polymorphisms in the pfcoronin gene which have been associated with decreased in vitro sensitivity to artesiminin.

No SNPs associated with artesiminin resistance were observed in the pfk13 propeller domain, nor in pfcoronin. One other study has to date, assessed the prevalence of polymorphisms in pfk13 in Pakistan [39]. This study reported nine non-synonymous and four synonymous mutations among 209 samples collected in 2016–2017. Each SNP was reported in less than 1% of the samples, and none of these SNPs corresponded to mutations that have been associated with artesiminin resistance. These
findings are in line with in vivo assessments of ACT efficacy in Pakistan. There has been no evidence of reduced ACT efficacy in Pakistan as of yet, with adequate clinical and parasitological responses of greater than 98% after treatment with AS+SP, AL, and dihydroartemisinin-piperaquine [40]. However, recent increases in AS+SP treatment failures in the North Eastern states of India, bordering with Myanmar, is a matter of concern for the continued westward spread of ACT resistance across from Southeast Asia [17]. Especially since molecular data have indicated that resistance to the SP partner drug is being established in Pakistan, although mutations that confer a high risk of SP treatment failure are still rare or non-existent [39, 40].

AL, on the other hand, remains efficacious in the North Eastern region of India [41, 42], and is currently the recommended first-line treatment for P. falciparum in the whole of the WHO Eastern Mediterranean Region, covering Afghanistan, Djibouti, Pakistan, Somalia and Sudan [1]. The efficacy of AL has been monitored in each of these countries, except in Djibouti. All therapeutic efficacy studies in these countries have shown low rates (<5%) of AL treatment failure, supporting its continued use as first-line treatment. However, whilst no SNPs associated with artemisinin resistance were observed in pfk13 and pfcort, the pfmdr1 N86 and D1246 alleles which have been associated with reduced sensitivity to lumefantrine [25, 28–36] were present in 83.8% and 100% of the isolates in this study, respectively (Table 2). The pfmdr1 N86 allele in particular, as well as increased pfmdr1 copy number, have shown to be significant independent risk factors for recrudescence in patients treated with AL [36]. The prevalence of pfmdr1 N86 has increased since the introduction of ACT in Pakistan in 2007, with a prevalence ranging from 55 to 67% in 2005–2007, and 96% in 2011, (Table 3) [43–45]. The pfmdr1 D1246 has been consistently reported in 100% of isolates since 2007. Pfmdr1 copy number was not analysed in this study due to its previously reported very low or non-existent presence in Pakistan.

Over a decade of wide-scale use of AL, mainly in African counties, has selected for pfcr76 and the pfmdr1 NFD haplotype N86/184F/D1246, with a parallel decline in pfcr76T and the pfmdr1 Y86Y/184Y/1246Y haplotype [31, 33, 35, 36, 46–48]. Parasites harbouring the pfmdr1 NFD haplotype have shown to able to re-infect patients whose lumefantrine blood concentrations were 15-fold higher than for parasites carrying the pfmdr1 YYY haplotype [32]. Despite this wide scale selection of SNPs associated with reduced sensitivity of lumefantrine, AL

### Table 3 Prevalence of polymorphisms in pfmdr1 and pfcr7 before and after introduction of AL in Pakistan

|                   | 2005–2007 (N = 240) [43] | 2007 (N = 28) [44] | 2011 (N = 171) [45] | 2018–2019 (N = 179) [current study] |
|-------------------|--------------------------|-------------------|-------------------|------------------------------------|
| **Pfmdr1 N86Y**   |                          |                   |                   |                                    |
| N86               | 43%                      | 67%               | 80%               | 77%                                |
| 86Y               | 45%                      | 33%<sup>a</sup>   | 4%                | 16%                                |
| N86Y (mixed)      | 12%                      | Not stated<sup>a</sup> | 16%               | 7%                                 |
| **Pfmdr1 Y184F**  |                          |                   |                   |                                    |
| Y184              | ND                       | ND                | 75%               | 83%                                |
| 184F              | ND                       | ND                | 0%                | 11%                                |
| Y184F (mixed)     | ND                       | ND                | 25%               | 6%                                 |
| **Pfmdr1 D1246Y** |                          |                   |                   |                                    |
| D1246             | ND                       | 100%              | 100%              | 100%                               |
| 1246Y             | ND                       | 0%                | 0%                | 0%                                 |
| D1246Y (mixed)    | ND                       | 0%                | 0%                | 0%                                 |
| **Pfmdr1 CNV**    |                          |                   |                   |                                    |
| Single copy       | 99.6% (231/232)<sup>b</sup> | ND              | 100%              | ND                                 |
| Multiple copy     | 0.4% (1/232)<sup>b</sup> | ND                | 0%                | ND                                 |
| **Pfcr7 K76T**    |                          |                   |                   |                                    |
| K76               | 7%                       | 0%                | 0%                | 2%                                 |
| 76T               | 93%                      | 100%              | 100%              | 91%                                |
| K76T (mixed)      | 0%                       | 0%                | 0%                | 7%                                 |

<sup>a</sup> Proportion of infections containing pfmdr1 86Y, proportion of which were mixed infections not stated

<sup>b</sup> (n/number of samples successfully analysed)

ND, not determined; CNV, copy number variation
remains highly effective across sub-Saharan Africa [49]. However, tracking changes in the prevalence of molecular markers of drug resistance can be a sensitive indicator of the selection of parasite populations, and may signal early decreases in drug susceptibility. In addition, decreasing efficacy of the partner drug may expose the artemisinin component of the ACT to selective pressure, and could facilitate emergence of new foci of resistance to artemisinin, as observed in the Greater Mekong Subregion [36]. Hence, in addition to therapeutic efficacy studies, further monitoring of the selection of molecular markers associated with both artemether and lumefantrine resistance in Pakistan, as in this study, is considered to be a critical tool to detect and prevent the spread of artemisinin resistance, and for preserving the efficacy of AL in the area [36].

Finally, the observed high prevalence (98.3%) of the chloroquine resistance associated pfert 76T allele is in line with previous assessments [43–45, 50, 51], and provides molecular evidence of chloroquine resistant P. falciparum in Pakistan. Although chloroquine was removed from the national guidelines for treatment of P. falciparum malaria more than 10 years ago, chloroquine is still recommended in the treatment of P. vivax and unconfirmed malaria infections [1]. Improper diagnosis of malaria, due to presumptive diagnosis based on clinical grounds and/or lack of diagnostic facilities (which are common practices in resource-limited countries such as Pakistan), is likely to sustain a high exposure of P. falciparum to chloroquine, maintaining the near fixation of the chloroquine resistant pfert 76T allele.

Conclusions

This study provides an update on the current prevalence of molecular markers associated with reduced P. falciparum sensitivity to artemether and/or lumefantrine in Pakistan. No mutations associated with artemisinin resistance were observed in pfk13 or pfcoronin. However, the prevalence of the pfmdr1 N86 and D1246 alleles, that have been associated with decreased susceptibility to lumefantrine, remain high. Although clinical and molecular data suggest that the current malaria treatment guidelines for P. falciparum are presently effective, close monitoring for artemisinin and lumefantrine resistance will be critical to ensure early detection and enhanced containment of emerging ACT resistance spreading across from Southeast Asia.

Abbreviations

ACT: Artemisinin-based combination therapy; AL: Artemether–lumefantrine; AS + SP: Artesunate–sulfadoxine–pyrimethamine; DI: Dera Ismail; DNA: Deoxyribonucleic acid; FR: Frontier region; KPK: Khyber Pakhtunkhwa; PCR: Polymerase chain reaction; PFcoronin: Plasmodium falciparum coronin gene; PFert: Plasmodium falciparum chloroquine resistance transporter gene; PFk13: Plasmodium falciparum Kelch 13 gene; PFmdr1: Plasmodium falciparum multidrug resistance 1 gene; RFLP: Restriction fragment length polymorphism; SNP: Single nucleotide polymorphism; WHO: World Health Organization.

Acknowledgements

The authors thank Adil Shah Mufti Farees ud Din Khattak, Waqas Ahmad, Sheikh Murtaza, Muhammad Yaqoob, Fahim Ahmad Akif, Muhammad Farman, and Waheed Khan in Pakistan for their help with the sample collection.

Authors’ contributions

AQK, MH, AAK, TAK, and FM designed the collection of samples in the field. AQK, LP, SL, BS, and UM designed and conducted the molecular analyses. AQK, LP, SL, and UM analysed the data. AQK and UM drafted the manuscript. All authors read and approved the final manuscript.

Funding

This work, as well as AQK doctoral studies, was supported by an International Research Support Initiative Program (IRISIP) grant (Grant number: IRISIP-42 BMS-24) sponsored by the Higher Education Commission (HEC), Islamabad, Pakistan. The molecular analyses conducted at Karolinska Institutet Stockholm, Sweden were supported in part by the Swedish Research Council (VR) (Grant number: 2017-05644) and KI Foundation and Funds (Grant number: 2018-01515). Open access funding provided by Karolinska Institute.

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate

Ethical approval for collecting human blood samples in this study was granted by the Research Ethical Committee (REC) of Kohat University of Science and Technology (KUST), Khyber Pakhtunkhwa, Pakistan [Ref. No. KUST/ Ethical Committee/18-04]. Written informed consent was obtained from all participants/guardians before obtaining clinical history and blood samples. Ethical approval for molecular work at Karolinska Institutet was granted by the Regional Ethics Committee in Stockholm, Sweden [2016/2286-32].

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

1 Department of Microbiology, Kohat University of Science and Technology, Kohat, Pakistan. 2 Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden. 3 Biosystems and Integrative Science Institute, Faculty of Sciences of the University of Lisbon, Lisbon, Portugal. 4 Department of Medical Lab Technology, The University of Haripur, Haripur, Pakistan. 5 Department of Biotechnology, Quaid-i-Azam University, Islamabad, Pakistan.

Received: 2 March 2020 Accepted: 29 May 2020

Published online: 08 June 2020

References

1. WHO. World malaria report. Geneva, World Health Organization. 2019. https://www.who.int/malaria/publications/world-malaria-report-2019/en/. Accessed 17 Jan 2020.
2. Directorate of Malaria Control. Pakistan Malaria Annual Report. 2019. http://dmc.gov.pk/documents/pdfs/Pakistan%20Malaria%20Annual%20Report%202019%20(02).pdf. Accessed 17 Jan 2020.
3. Menard D, Dondorp A. Antimalarial drug resistance: a threat to malaria elimination. Cold Spring Harb Perspect Med. 2017;7:a025619.
4. WHO. Artemisinin resistance and artemisinin-based combination therapy efficacy: status report. Geneva, World Health Organization. 2018. https://apps.who.int/iris/handle/10665/274362. Accessed 17 Jan 2020.
5. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2009;361:453–67.
6. Noedl H, Se Y, Schaechter K, Smith BL, Socheat D, Fukuda MM. Evidence of artemisinin-resistant malaria in western Cambodia. N Engl J Med. 2008;359:2619–20.
7. Tun KM, Imwong M, Lwin KM, Win AA, Hlaing TM, Hlaing T, et al. Spread of artemisinin-resistant Plasmodium falciparum in Myanmar: a cross-sectional survey of the K13 molecular marker. Lancet Infect Dis. 2015;15:415–21.
8. Whittaker M. Update from the Asia Pacific Malaria Elimination Network (APMEN). Malar J. 2012;11(Suppl 1):OS4.
9. Arey F, Witkowski B, Amaratunga C, Beghain J, Langlois A-C, Khim N, et al. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature. 2014;505:50–5.
10. Stainer J, Gnadig NF, Witkowski B, Amaratunga C, Dunu V, Ramadani AP, et al. K13-propeller mutations confer artemisinin resistance in Plasmodium falciparum clinical isolates. Science. 2015;347:428–31.
11. Chenet SM, Akinyi Okoth S, Huber CS, Chandrabose J, Lucchi NW, Talundzic E, et al. Independent emergence of the Plasmodium falciparum kelch propeller domain mutant allele CS80Y in Guyana. J Infect Dis. 2016;213:472–5.
12. Miotto O, Selkhor M, Tachibana S-I, Yamauchi M, Pearson RD, Amato R, et al. Emergence of artemisinin-resistant Plasmodium falciparum with kelch13 CS80Y mutations on the island of New Guinea. bioRxiv. 2019. https://doi.org/10.1101/621813.
13. Tacoli C, Gai PP, Bayingana C, Sifft K, Geus D, Ndoli J, et al. Artemisinin-resistant malaria in western Cambodia: dihydroartemisinin-piperaquine open-label multicenter clinical assessment. Antimicrob Agents Chemother. 2015;59:4719–26.
14. Phyo A. Declining efficacy of mefloquine-artesunate combination and relative role of drug-resistant molecular markers: Thai-Myanmar Border 2003–2013. Int J Infect Dis. 2016;45:15.
15. Das S, Saha B, Hati AK, Roy S. Evidence of artemisinin-resistant Plasmodium falciparum malaria in eastern India. J Biosci. 2013;38:1507–11.
16. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, et al. Temporal trends of molecular markers associated with artemether-lumefantrine resistance in Bagamoyo district, Tanzania. Malar J. 2013;12:103.
17. Malmberg N, Mgba B, Phyo PE, Larsson E, Jovel I, Hjalmarsson A, et al. Temporal trends of molecular markers associated with artemether-lumefantrine tolerance/resistance in in Khambabasi district, Tanzania. Malar J. 2012;11(Suppl 1):O54.
18. Khan et al. Malar J (2020) 19:206
43. Ghanchi NK, Ursing J, Beg MA, Veiga MI, Jafri S, Martensson A. Prevalence of resistance associated polymorphisms in Plasmodium falciparum field isolates from southern Pakistan. Malar J. 2011;10:18.

44. Khatoon L, Baliraine FN, Bonizzoni M, Malik SA, Yan G. Prevalence of antimalarial drug resistance mutations in Plasmodium vivax and P. falciparum from a malaria-endemic area of Pakistan. Am J Trop Med Hyg. 2009;81:525–8.

45. Khattak AA, Venkatesan M, Jacob CG, Artimovich EM, Nadeem MF, Nighat F, et al. A comprehensive survey of polymorphisms conferring anti-malarial resistance in Plasmodium falciparum across Pakistan. Malar J. 2013;12:300.

46. Kavishe RA, Paulo P, Kaaya RD, Kalinga A, van Zwetselaar M, Chilongola J, et al. Surveillance of artemether-lumefantrine associated Plasmodium falciparum multidrug resistance protein-1 gene polymorphisms in Tanzania. Malar J. 2014;13:264.

47. Thomsen TT, Ishengoma DS, Mmbando BP, Lusingu JP, Vestergaard LS, Theander TG, et al. Prevalence of single nucleotide polymorphisms in the Plasmodium falciparum multidrug resistance gene (Pfmdr-1) in Korogwe District in Tanzania before and after introduction of artemisinin-based combination therapy. Am J Trop Med Hyg. 2011;85:979–83.

48. Yeka A, Kigozi R, Conrad MD, Lugemwa M, Okui P, Katureebe C, et al. Artesunate/amodiaquine versus artemether/lumefantrine for the treatment of uncomplicated malaria in Uganda: a randomized trial. J Infect Dis. 2016;213:1134–42.

49. Conrad MD, Rosenthal PJ. Antimalarial drug resistance in Africa: the calm before the storm? Lancet Infect Dis. 2019;19:e338–51.

50. Sahar S, Tanveer A, Ali A, Bilal H, Muhammad Saleem R. Pfcrt gene in Plasmodium falciparum field isolates from Muzaffargarh, Pakistan. J Arthropod Borne Dis. 2015;9:204–14.

51. Rawasia WF, Sridaran S, Patel JC, Abdallah J, Ghanchi NK, Barnwell JW, et al. Genetic backgrounds of the Plasmodium falciparum chloroquine resistant transporter (pfcrt) alleles in Pakistan. Infect Genet Evol. 2012;12:278–81.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.